Novo Nordisk focuses on diabetes care and hormone replacement therapy, self-described as a leader in this sector.

Novo Nordisk

Ask Oz

HemaGo

Novo Rocket Trooper

Growth Evaluation Tool

Virtual Joint Bleed

Coags Uncomplicated

Speaker Slides

Domain Not Resolving

Apple Mobile Web Clips Icon

DNSSEC

Google Maps

Amazon

nginx

US Privacy User Signal Mechanism

IPv6

jsDelivr

Google Apps for Business

Co-Founder & Director

Bhavesh Fatania

Managing Assistant General Counsel, Intellectual Property

Chloe Jiang

Executive Vice President & Senior VP, Head of North America Operations and President of NNI

Douglas J. Langa

Legal

Leon Lum

Melissa DeHonney

Vice President

Anders Nørbygaard

VP Sales, Central Area

Brian Krebs

Dan Arnott

Senior VP & Project Assistant

Ditte Bræstrup

Vice President, Pricing, Contract Ops & Reimbursement

Farruq Jafery

Sylvie Gregoire

Marc Newman

Thomas Koestler

Evi Mathiou

Karen Katen

Shamim Rahman

Lars Køppler

Lars Sorensen

President & CEO

Marianne Hedegaard

Service Manager (eDevice/eSolution in Clinical Trials)

Maziar Mike Doustdar

Executive Vice President, International Operations

Maura Reilly

Associate Director

Monique Carter

EVP People & Organisation

Henrik Gürtler

Corporate Vice President of Human Resource Development

Greg Jones

Vice President, Legal Affairs

Christian Wenzel Tornøe

Principal Scientist

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

European Union (EU) Companies With More Than 100 Employees (Top 10K)

Investors Active in Provence-Alpes-Cote d'Azur

European Union (EU) Public Companies With More Than $500 in Revenue

Pharmaceutical Companies (Top 10K)

Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.

Post-IPO Equity - Novo Nordisk

Bagsværd

Hovedstaden

Denmark

Europe

NanoVation Bolsters Board, Captures Capital to Advance Novel Biotech

Weight-loss drug coverage rises among largest US employers, Mercer survey finds

Endocrinology Drugs Market Analysis by Therapy Area, Distribution Channel and Region - A Forecasted $53.85 Billion Industry by 2030

Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

Novo Nordisk's Weight Loss Drug to Start Sales in China

Exclusive-Medicaid fuels US coverage of Novo, Lilly weight-loss drugs

Health stocks slide as Trump picks vaccine skeptic Kennedy

Medications designed to manage blood sugar levels in individuals with type 2 diabetes by mimicking the incretin hormones that the body usually produces to stimulate insulin release.

Pharmaceutical solutions aimed at assisting weight management and reducing obesity-related health risks.

A treatment for haemophilia A that reduces bleeding episodes, administered either weekly or monthly.

A recycling program for used medical devices, particularly injection pens, to reduce plastic waste and promote sustainability.

United States

North America

Germany

United Kingdom

India

Asia

HTML5

Google Maps API

Valimail

Google Drive

Google Tag Manager

Facebook Comments

DigiCert

Apache Server

Google Fonts

Modernizr

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Dicerna Pharmaceuticals, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 23, 2024 9:07 PM	081115d8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 23, 2024 9:07 PM	65358d00
crunchbase trigger	general	Nov 25, 2024 9:06 AM	d6610fde
crunchbase profile	general	Nov 25, 2024 10:23 AM	081d4e32
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 4:20 PM	b035bd30
peers	general	Sep 23, 2024 9:07 PM	33f9dae3
news basic	general	Sep 23, 2024 9:07 PM	dca4cca9
bundesanzeiger	filings
financials download nd	financials
private financials	financials

DRNA

COM:DICERNA

Novo Nordisk

Last Close

38.22

01/01 00:00

Volume Today

5.54M

Avg: -